Patent SG-11201806455P-A (SG)
Title: Human antibodies and binding fragments thereof to tenascin
Inventor: HEXTALL PATRICK
IPC: G01N33/68
Filed: 2017-02-10
Abstract: aTA EGF-L TNIII FBG W O 17 / 1375 42 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/137542 Al 17 August 2017 (17.08.2017) WIPO I PCT (51) International Patent Classification: A61K 39/395 (2006.01) C07K 16/18 (2006.01) C07K 14/78 (2006.01) GO1N 33/68 (2006.01) (21) International Application Number: PCT/EP2017/052974 (22) International Filing Date: 10 February 2017 (10.02.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 1602414.3 10 February 2016 (10.02.2016) GB (71) Applicant: NASCIENT LIMITED [GB/GB]; Imperial In- novations Ltd, 52 Princes Gate, Exhibition Road, London SW7 2PG (GB). (72) Inventors: HEXTALL, Patrick; c/oNascient Limited, Im- perial Innovations, 52 Princes Gate, London SW7 2PG (GB). MIDWOOD, Kim Suzanne; Kennedy Institute of Rheumatology, Roosevelt Drive Headington, Headington, Oxford OX3 7FY (GB). CULBERT, Eric; c/oNascient Limited, Imperial Innovations, 52 Princes Gate, London SW7 2PG (GB). (74) Agents: STERLING IP et al.; Orion House, Bessemer Road, Welwyn Garden City Hertfordshire AL7 1HH (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) (54) Title: HUMAN ANTIBODIES AND BINDING FRAGMENTS THEREOF TO TENASCIN FIGURE 9 (57) : The present disclosure relates fully antibodies and binding fragments, to a Tenascin, in particular the FBG domain of a Tenascin, which are potentially less immunogenic than the parent antibody. The disclosure also relates to composition comprising the antibody or binding fragment and use of any one of the same for diagnosis, prognosis and/or treatment of disorders such as those associated with chronic inflammation. The disclosure further provides methods of making said antibodies. 111111111111110111011111111111010111110111011101111111110011111011111111111110111111